These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20020366)

  • 21. Investigation of charge variants of rViscumin by two-dimensional gel electrophoresis and mass spectrometry.
    Lutter P; Meyer HE; Langer M; Witthohn K; Dormeyer W; Sickmann A; Blüggel M
    Electrophoresis; 2001 Aug; 22(14):2888-97. PubMed ID: 11565784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doping in the recombinant era: strategies and counterstrategies.
    Azzazy HM; Mansour MM; Christenson RH
    Clin Biochem; 2005 Nov; 38(11):959-65. PubMed ID: 16286094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent?
    Rogol AD
    Growth Horm IGF Res; 2009 Aug; 19(4):294-9. PubMed ID: 19487146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometric identification of peptide hormones in doping-control analysis.
    Thevis M; Schänzer W
    Analyst; 2007 Apr; 132(4):287-91. PubMed ID: 17554406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capillary column chromatography improves sample preparation for mass spectrometric analysis: complete characterization of human alpha-enolase from two-dimensional gels following in situ proteolytic digestion.
    Reid GE; Rasmussen RK; Dorow DS; Simpson RJ
    Electrophoresis; 1998 May; 19(6):946-55. PubMed ID: 9638941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mass spectrometric determination of insulins and their degradation products in sports drug testing.
    Thevis M; Thomas A; Schänzer W
    Mass Spectrom Rev; 2008; 27(1):35-50. PubMed ID: 18000882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.
    Thevis M; Wilkens F; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(22):3393-402. PubMed ID: 17051614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation.
    de Kock SS; Rodgers JP; Swanepoel BC
    Rapid Commun Mass Spectrom; 2001; 15(14):1191-7. PubMed ID: 11445902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin.
    Thevis M; Thomas A; Schänzer W
    Handb Exp Pharmacol; 2010; (195):209-26. PubMed ID: 20020367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demographic factors influencing the GH system: Implications for the detection of GH doping in sport.
    Nelson AE; Ho KK
    Growth Horm IGF Res; 2009 Aug; 19(4):327-32. PubMed ID: 19481485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Technology insight: detecting growth hormone abuse in athletes.
    Bidlingmaier M; Strasburger CJ
    Nat Clin Pract Endocrinol Metab; 2007 Nov; 3(11):769-77. PubMed ID: 17955018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive mass spectrometric analysis of the 20S proteasome complex.
    Huang L; Burlingame AL
    Methods Enzymol; 2005; 405():187-236. PubMed ID: 16413316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteolytic-based method for the identification of human growth hormone.
    Wisniewski ES; Rees DK; Chege EW
    J Forensic Sci; 2009 Jan; 54(1):122-7. PubMed ID: 19120827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene doping: the hype and the harm.
    McKanna TA; Toriello HV
    Pediatr Clin North Am; 2010 Jun; 57(3):719-27. PubMed ID: 20538153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone.
    Jiang H; Wu SL; Karger BL; Hancock WS
    Biotechnol Prog; 2009; 25(1):207-18. PubMed ID: 19224592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of human insulin-like growth factor-1 in deer antler velvet supplements.
    Cox HD; Eichner D
    Rapid Commun Mass Spectrom; 2013 Oct; 27(19):2170-8. PubMed ID: 23996390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of doping with recombinant human growth hormone.
    He C; Wu M
    Bioanalysis; 2009 Aug; 1(5):953-65. PubMed ID: 21083065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid identification of somatropin by peptide-mass fingerprinting, using MALDI-TOF mass spectrometry.
    Amini A
    Pharmeur Sci Notes; 2009 Mar; 2009(1):11-6. PubMed ID: 19275868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing.
    Thevis M; Loo JA; Loo RR; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(3):297-304. PubMed ID: 17200979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.